Ensign Peak Advisors Inc Sells 3,750 Shares of Henry Schein, Inc. $HSIC

Ensign Peak Advisors Inc trimmed its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 9.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,736 shares of the company’s stock after selling 3,750 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Henry Schein were worth $2,611,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in HSIC. ANTIPODES PARTNERS Ltd bought a new stake in shares of Henry Schein during the 2nd quarter worth about $43,000. Steph & Co. bought a new stake in Henry Schein during the second quarter worth approximately $44,000. CX Institutional boosted its position in Henry Schein by 107.3% during the second quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after purchasing an additional 337 shares during the period. TD Private Client Wealth LLC grew its holdings in Henry Schein by 103.0% during the second quarter. TD Private Client Wealth LLC now owns 668 shares of the company’s stock valued at $49,000 after purchasing an additional 339 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Henry Schein in the first quarter valued at approximately $71,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Henry Schein in a report on Friday, October 31st. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Wells Fargo & Company raised their price target on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Evercore ISI lifted their price objective on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Finally, Morgan Stanley increased their target price on Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research note on Wednesday, November 5th. Five research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Henry Schein presently has an average rating of “Hold” and a consensus target price of $76.08.

Henry Schein Stock Performance

NASDAQ HSIC opened at $75.25 on Thursday. The company’s fifty day moving average is $67.47 and its two-hundred day moving average is $69.34. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The firm has a market capitalization of $8.86 billion, a price-to-earnings ratio of 24.27, a P/E/G ratio of 2.06 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business had revenue of $3.34 billion during the quarter, compared to analyst estimates of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Equities research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.